Liu Junjie, Xue Ping, Deng Jingwen
Department of General Surgery, Guangzhou Panyu Central Hospital Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou Medical University Central Laboratory, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Medicine (Baltimore). 2018 Feb;97(8):e9863. doi: 10.1097/MD.0000000000009863.
Cholangiocarcinoma is a malignant neoplasia that originates in the bile ducts. Most patients with cholangiocarcinoma are inoperable at the time of diagnosis. photodynamic therapy (PDT) is a fairly well accepted treatment in clinical practice for nonresectable cholangiocarcinoma (NCC) but lack of quantitatively assessment. Herein, we present a protocol for a systematic review to identify the efficacy of PDT in patients with NCC.
We will search PUBMED, SpringerLink, Cochrane Library, the Chinese Biomedical database (CBM), WanFang data, China National Knowledge Infrastructure (CNKI) up to December 2017. Studies will be screened by title, abstract, and full text independently and in duplicate. Studies that report PDT in patients with nonresectable cholangiocarcinoma will be eligible for inclusion. Outcome variables will be assessed included survival benefit, health status and quality of life, and adverse events with photodynamic therapy. Assessment of risk of bias and data synthesis will be performed using Revman software. The hazard ratios will be extracted from the survival curves using Tierney Method. Heterogeneity among studies will be assessed using the I statistic.
This study will review randomized controlled trials, cohort studies, or retrospective studies and quantitatively assess the efficacy of PDT in patients with NCC for the latest evidence-based recommendation.
This study will evaluate therapeutic effect of PDT in patients with NCC systematically. We expect that the results from this systematic review for clinical trials will help inform clinical practice in NCC.
胆管癌是一种起源于胆管的恶性肿瘤。大多数胆管癌患者在确诊时已无法进行手术。光动力疗法(PDT)在临床实践中是一种治疗不可切除胆管癌(NCC)被广泛接受的方法,但缺乏定量评估。在此,我们提出一项系统评价方案,以确定PDT对NCC患者的疗效。
我们将检索截至2017年12月的PUBMED、SpringerLink、Cochrane图书馆、中国生物医学数据库(CBM)、万方数据、中国知网(CNKI)。研究将由两人独立地通过标题、摘要和全文进行筛选。报告PDT治疗不可切除胆管癌患者的研究将符合纳入标准。将评估的结局变量包括生存获益、健康状况和生活质量以及光动力疗法的不良事件。将使用Revman软件进行偏倚风险评估和数据合成。将使用Tierney方法从生存曲线中提取风险比。将使用I统计量评估研究间的异质性。
本研究将回顾随机对照试验、队列研究或回顾性研究,并定量评估PDT对NCC患者的疗效,以获得最新的循证医学推荐。
本研究将系统评价PDT对NCC患者的治疗效果。我们期望该系统评价的结果将有助于为NCC的临床实践提供参考。